阿巴西普治疗早期风湿性多肌痛(ALORS):一项概念验证、随机、安慰剂对照、平行组试验
在法国五个中心纳入34例近期起病(<6个月)且无巨细胞动脉炎征象的风湿性多肌痛患者,1:1随机接受每周皮下阿巴西普125 mg或安慰剂12周。作者认为阿巴西普单药效应不足以支持在早期风湿性多肌痛中开展更大规模研究。
要点
- 阿巴西普组8/16(50%)vs 安慰剂组15/18(83%)发生不良事件;严重不良事件阿巴西普组1/16(6%)vs 安慰剂组3/18(17%)。
- 作者认为阿巴西普单药效应不足以支持在早期风湿性多肌痛中开展更大规模研究。
核心结论
- 作者认为阿巴西普单药效应不足以支持在早期风湿性多肌痛中开展更大规模研究。
- 作者指出这仅是决定是否在早期风湿性多肌痛中开展更大规模研究的第一步,并不排除阿巴西普对糖皮质激素依赖型风湿性多肌痛的潜在效应。
研究设计与样本
- 概念验证、随机、双盲、安慰剂对照、平行组试验,在法国五个中心(Brest、Le Mans、Morlaix、Dinan、Saint Malo和Strasbourg)招募患者。
- 纳入近期起病(<6个月)风湿性多肌痛且CRP PMR-AS>17、无巨细胞动脉炎临床及[18F]氟脱氧葡萄糖PET-CT征象者。
- 34例患者(22例女性、12例男性)于2018年12月13日至2021年10月21日随机1:1接受每周皮下阿巴西普125 mg或匹配安慰剂12周,后续至第36周根据疾病活动给予糖皮质激素治疗。
- 主要终点为第12周无糖皮质激素且无补救治疗下达到低疾病活动(CRP PMR-AS≤10);研究把握度设定为证明组间应答率差异60%。
主要发现
- 不良事件阿巴西普组8/16(50%)vs 安慰剂组15/18(83%)。
- 严重不良事件阿巴西普组1/16(6%)vs 安慰剂组3/18(17%)。
- 无死亡或新的安全性问题。
关键数值与推荐
- 主要终点低疾病活动定义为CRP PMR-AS≤10。
- 纳入标准为近期起病(<6个月)风湿性多肌痛且CRP PMR-AS>17。
- 阿巴西普剂量为每周皮下125 mg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出本研究仅为决定是否在早期风湿性多肌痛中开展更大规模研究的第一步。
- 作者指出本研究不排除阿巴西普对糖皮质激素依赖型风湿性多肌痛的潜在效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medium-dose glucocorticoids can improve symptoms in nearly all patients with polymyalgia rheumatica. According to its good safety profile, abatacept could be used instead of glucocorticoids in early polymyalgia rheumatica. We aimed to determine whether the efficacy of abatacept is sufficient to justify larger studies in early polymyalgia rheumatica. METHODS: To evaluate whether abatacept allows low disease activity without glucocorticoids in early polymyalgia rheumatica, we conducted a proof-of-concept, randomised, double-blind, placebo-controlled, parallel-group trial. Participants were recruited from five centres in France (in Brest, Le Mans, Morlaix, Dinan and Saint Malo, and Strasbourg) and were included if they had recent-onset (<6 months) polymyalgia rheumatica with a C-reactive protein (CRP) polymyalgia rheumatica activity score (PMR-AS) of more than 17 without any signs or symptoms of giant cell arteritis (clinical and [18F]fluorodeoxyglucose PET-CT evaluation). Participants were randomly assigned (1:1) to receive weekly subcutaneous abatacept (125 mg) or matching placebo, with glucocorticoid rescue therapy allowed in cases of high disease activity, for 12 weeks, and then glucocorticoid treatment based on disease activity, until week 36. Investigators, patients, outcome assessors, and sponsor personnel were masked to group assignments. The primary endpoint was low disease activity (CRP PMR-AS ≤10) at week 12 without glucocorticoids and without rescue treatment. The study was powered to demonstrate a 60% difference in response rates between groups. Open-ended adverse events were collected at each visit by clinicians and were categorised following system organ class classification after study completion. The ALORS trial is registered with ClinicalTrials.gov, NCT03632187. FINDINGS: 34 patients (22 women and 12 men) were randomly assigned between Dec 13, 2018, and Oct 21, 2021. All patients who had been randomly assigned were included in the analysis. The primary endpoint was reached by eight (50%) of 16 patients in the abatacept group and four (22%) of 18 patients in the placebo group (relative risk 2·2 [0·9-5·5]); crude p=0·15; adjusted p=0·070). Eight (50%) patients in the abatacept and 15 (83%) in the placebo group had adverse events. Four patients (one [6%] in the abatacept group and three [17%] in the placebo group) had serious adverse events. There were no deaths or new safety concerns. INTERPRETATION: This study suggests that the effect of abatacept alone is not strong enough to justify larger studies in early polymyalgia rheumatica. This is only a first step in deciding whether a larger study should be conducted in early polymyalgia rheumatica and does not exclude a potential effect of abatacept in glucocorticoid-dependent polymyalgia rheumatica. FUNDING: BMS Pharma France.
引用
- Saraux A, Le Henaff C, Dernis E, et al. Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial. Lancet Rheumatol. 2023. PMID: 38251563. doi:10.1016/S2665-9913(23)00246-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。